BTK and lymphoma: Similarly, the BTK inhibitor acalabrutinib [45,46] and the novel combination of lenalidomide with rituximab (R2) [42,47,48,49] have shown impressive results in difficult-to-treat lymphoma variants, and may offer therapeutic alternatives for PLPN patients.